Scarica l'app Stockscreener
30.36
3.31%
-1.04
Dopo l'orario di chiusura:
30.36
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALKS Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$31.40
Aprire:
$31.02
Volume 24 ore:
1.46M
Relative Volume:
0.80
Capitalizzazione di mercato:
$4.74B
Reddito:
$1.51B
Utile/perdita netta:
$333.35M
Rapporto P/E:
15.57
EPS:
1.95
Flusso di cassa netto:
$315.22M
1 W Prestazione:
+5.53%
1M Prestazione:
+1.00%
6M Prestazione:
+3.65%
1 anno Prestazione:
+25.98%
Intervallo 1D:
$30.18
$31.27
Intervallo di 1 settimana:
$28.31
$31.99
Portata 52W:
$22.90
$36.45
Alkermes Plc Stock (ALKS) Company Profile
Nome
Alkermes Plc
Settore
Telefono
00-353-1-772-8000
Indirizzo
CONNAUGHT HOUSE, DUBLIN 4
Confronta ALKS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
30.36 | 4.74B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
149.87 | 69.33B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.17 | 48.09B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.67 | 46.34B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.12 | 18.47B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
295.02 | 13.57B | 2.76B | 1.11B | 898.10M | 22.77 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | Aggiornamento | UBS | Sell → Neutral |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-11-05 | Aggiornamento | Stifel | Hold → Buy |
| 2024-06-17 | Iniziato | TD Cowen | Buy |
| 2024-03-19 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-20 | Downgrade | UBS | Neutral → Sell |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-10-24 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-10-17 | Iniziato | UBS | Neutral |
| 2022-11-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-08-16 | Iniziato | Piper Sandler | Neutral |
| 2022-04-22 | Ripresa | Goldman | Buy |
| 2022-04-20 | Iniziato | Goldman | Buy |
| 2022-01-27 | Aggiornamento | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | Iniziato | Citigroup | Neutral |
| 2021-10-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-09-02 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-10-15 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-07-30 | Downgrade | Goldman | Neutral → Sell |
| 2020-02-14 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | Reiterato | H.C. Wainwright | Neutral |
| 2020-02-14 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2020-01-31 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-05-31 | Iniziato | H.C. Wainwright | Neutral |
| 2019-05-01 | Downgrade | Citigroup | Buy → Neutral |
| 2018-12-19 | Downgrade | Goldman | Neutral → Sell |
| 2018-12-14 | Iniziato | Wolfe Research | Underperform |
| 2018-12-13 | Downgrade | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | Iniziato | Piper Jaffray | Neutral |
| 2018-08-07 | Iniziato | Stifel | Hold |
| 2018-06-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
Mostra tutto
Alkermes Plc Borsa (ALKS) Ultime notizie
Alkermes plc (ALKS): Among Billionaire Jim Simons’ RenTech’s Small-Cap Stock Picks with Huge Upside Potential - Insider Monkey
Alkermes plc (NASDAQ:ALKS) Q1 2025 Earnings Call Transcript - Insider Monkey
Alkermes has near-term catalyst with narcolepsy data, says H.C. Wainwright - TipRanks
BlackRock, Inc. Reduces Stake in Alkermes PLC: A Detailed Analysis - GuruFocus
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes plc To Contact The Firm - ACCESS Newswire
RBC Capital Raises Price Target for Alkermes (ALKS) to $40 | ALKS Stock News - GuruFocus
Alkermes' Q1 Earnings and Revenues Fall Short of Estimates - Nasdaq
Alkermes (ALKS) Reaffirms 2025 Financial Outlook and Awaits Key Trial Results | ALKS Stock News - GuruFocus
Alkermes (ALKS) Price Target Raised to $41 by Baird Analyst | AL - GuruFocus
Baird Increases Price Target for Alkermes (ALKS) on Promising Ou - GuruFocus
RBC Raises Price Target on Alkermes to $40 From $39, Keeps Sector Perform Rating - marketscreener.com
Alkermes PLC (ALKS) Q1 2025 Earnings Call Highlights: Strong Proprietary Product Growth and ... - Yahoo Finance
Alkermes: Q1 Earnings Snapshot - MySA
Alkermes plc Reports Q1 2025 Financial Results - TipRanks
Alkermes plc Earnings Call Highlights Growth and R&D Progress - TipRanks
Alkermes Plc earnings missed by $0.18, revenue fell short of estimates - Investing.com Nigeria
Alkermes: Label Expansion Of LYBALVI With Ongoing Pediatric Trial Possible (NASDAQ:ALKS) - Seeking Alpha
Chondrosarcoma Market: Epidemiology, Therapies, Companies, - openPR.com
Alkermes Q1 2025 Earnings Call Transcript - MarketBeat
Here's What Key Metrics Tell Us About Alkermes (ALKS) Q1 Earnings - Yahoo Finance
Alkermes Q1 Earnings, Revenue Decline - marketscreener.com
Alkermes Plc reports results for the quarter ended March 31Earnings Summary - TradingView
Alkermes PLC Q1 2025 Earnings: EPS of $0.13 Beats Estimate, Reve - GuruFocus
Alkermes (ALKS) Misses Q1 Earnings and Revenue Estimates - Yahoo Finance
Alkermes (ALKS) Exceeds Q1 Revenue Expectations and Advances Ore - GuruFocus
Alkermes plc Reports First Quarter 2025 Financial Results | ALKS Stock News - GuruFocus
Earnings Flash (ALKS) Alkermes Posts Q1 EPS of $0.13, vs. FactSet Est of $0.05 - marketscreener.com
Earnings Flash (ALKS) ALKERMES PLC Reports Q1 Revenue $306.5M, vs. FactSet Est of $302.9M - marketscreener.com
Alkermes plc Reports First Quarter 2025 Financial Results - PR Newswire
Do Options Traders Know Something About Alkermes Stock We Don't? - TradingView
Drug Detoxification Market Is Booming Worldwide 2025-2032 | - openPR.com
New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD) - PR Newswire
How to Take Advantage of moves in (ALKS) - news.stocktradersdaily.com
UBS Adjusts Alkermes (ALKS) Price Target Amid Softer Q1 Guidance - GuruFocus
Beyond The Numbers: 6 Analysts Discuss Alkermes Stock - Benzinga
UBS Adjusts Alkermes Public Price Target to $33 From $38, Maintains Neutral Rating - marketscreener.com
Press Release Distribution & PR Platform - ACCESS Newswire
Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline - Yahoo Finance
U.S. Opioid Withdrawal Treatment Market Emerging Trends - openPR.com
Stocks Update From Health Care Sector -- DexCom, Alkermes, BioCryst Pharmaceuticals, Anacor Pharmaceuticals and Endologix - ADVFN
First Week of June 20th Options Trading For Alkermes (ALKS) - Nasdaq
Alkermes plc's (NASDAQ:ALKS) Earnings Are Not Doing Enough For Some Investors - simplywall.st
Alkermes spinoff Mural plunges on plans to halt ovarian cancer trial - MSN
Alkermes price target raised to $35 from $34 at BofA - MSN
Alkermes to Report First Quarter Financial Results on May 1, 2025 - GuruFocus
Alkermes to Report First Quarter Financial Results on May 1, 2025 – Company Announcement - Financial Times
Controlled Release Drug Delivery Market Is Booming So Rapidly - openPR.com
Alkermes' CFO Iain Brown passes away - MSN
Alkermes (ALKS) Announces CFO Transition Following Iain M. Brown's Passing - GuruFocus
Alkermes' CFO Iain Brown passes away (ALKS:NASDAQ) - Seeking Alpha
Alkermes CFO Iain M. Brown passes away By Investing.com - Investing.com India
Alkermes Plc Azioni (ALKS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.45%
8.36%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):